Title: Ewing's sarcoma: A combined approach in the management
| dc.contributor.author | G.C. Pant | |
| dc.contributor.author | B. Sanyal | |
| dc.contributor.author | K. Sahni | |
| dc.contributor.author | S.M. Tuli | |
| dc.contributor.author | T.P. Srivastava | |
| dc.date.accessioned | 2026-02-09T10:24:34Z | |
| dc.date.issued | 1981 | |
| dc.description.abstract | Twenty-seven histologically confirmed cases of localised Ewing's sarcoma were treated by two different regimes. Radiotherapy alone was used in 13 cases and a combination of chemotherapy and radiotherapy in 14. Single agent chemotherapy (cyclophosphamide) was given sequentially in nine patients and cyclophosphamide and actinomycin-D in five. There is a significant difference in the response to these different regimes. Only 69.2% of patients treated by radiotherapy alone were disease-free, for a median period of 10.4 months and metastases were noticed in 53.8% of cases. The disease-free survival in patients treated by combination therapy (radiotherapy and chemotherapy) was 18.4 months and metastases were seen in only 42.9%. However, no metastases were seen in patients who received cyclophosphamide and actinomycin-D, during a period of 14 months and only one patient showed residual disease. It is concluded that the addition of cyclophosphamide alone is not adequate in the management of Ewing's sarcoma. Actinomycin-D in addition to cyclophosphamide has improved the disease-free survival period significantly. The optimum dose of radiotherapy and its combination with other chemotherapeutic agents needs further trials to find the best and most suitable schedule. © 1981 Royal College of Radiologists. | |
| dc.identifier.doi | 10.1016/S0009-9260(81)80309-1 | |
| dc.identifier.issn | 99260 | |
| dc.identifier.uri | https://doi.org/10.1016/S0009-9260(81)80309-1 | |
| dc.identifier.uri | https://dl.bhu.ac.in/bhuir/handle/123456789/58244 | |
| dc.title | Ewing's sarcoma: A combined approach in the management | |
| dc.type | Publication | |
| dspace.entity.type | Article |
